|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:affects
|
gptkb:Central_nervous_system
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:category
|
Antiparkinsonian agents
CNS agents
Neurotransmitter agents
Psychostimulants
|
|
gptkbp:cause
|
Addiction
Sleep disturbances
Dyskinesia
|
|
gptkbp:contraindication
|
gptkb:Psychosis
Narrow-angle glaucoma
|
|
gptkbp:discoveredIn
|
20th century
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dopaminergic Agents
|
|
gptkbp:includes
|
gptkb:Methylphenidate
gptkb:Levodopa
gptkb:Bupropion
MAO-B inhibitors
Dopamine agonists
COMT inhibitors
Amantadine
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
Antipsychotics
Antihypertensives
|
|
gptkbp:mechanismOfAction
|
Affect dopamine neurotransmission
|
|
gptkbp:metabolism
|
Liver enzymes
|
|
gptkbp:regulates
|
emotion
Motor control
Prolactin secretion
Reward pathways
|
|
gptkbp:routeOfAdministration
|
gptkb:Oral
Intravenous
Transdermal
|
|
gptkbp:sideEffect
|
gptkb:Nausea
gptkb:Hallucinations
Orthostatic hypotension
Impulse control disorders
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:Restless_legs_syndrome
gptkb:Attention_deficit_hyperactivity_disorder
Depression
|
|
gptkbp:bfsParent
|
gptkb:D010141
|
|
gptkbp:bfsLayer
|
7
|